GW confident epilepsy drug will get NHS funding despite NICE rejection

The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of childhood epilepsy.